31 completed, 1 terminated, 1 unknown. 10 Phase 1, 7 Phase 2, 6 Phase 4, 5 Early Phase 1, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 7 | Completed 7 |
| Phase 4 | 6 | Completed 5, Terminated 1 |
| Early Phase 1 | 5 | Completed 5 |
| Not applicable | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
Follow Vi polysaccharide vaccine, typhoid: new trials by email Literature Review of Vi polysaccharide vaccine, typhoid trials Research Report on Vi polysaccharide vaccine, typhoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women Iron supplementation, MenACWY vaccine, COVID-19 vaccine - Iron Deficiency Anemia | Not applicable | Unknown | Swiss Federal Institute of Technology | 180 | 2023-11-01 | 2024-01-24 |
| Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women Oral iron supplementation (pre-treatment), COVID-19 vaccine, MenACWY vaccine - Iron Deficiency Anemia | Not applicable | Completed | Nicole Stoffel | 180 | 2023-07-01 | 2025-12-26 |
| Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine - Typhoid Fever | Phase 1 | Completed | GlaxoSmithKline | 97 | 2022-11-28 | 2025-01-24 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| Persistent Readiness Through Early Prediction Immunization Study Pneumovax 23, Typhim VI, Saline - Inflammatory Response | Early Phase 1 | Completed | Texas A&M University | 249 | 2022-02-08 | 2023-02-14 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) Vi-DT Typhoid Conjugate Vaccine, PQed Typhoid Conjugate Vaccine, Vi Polysaccharide Vaccine - Safety Issues, Immunogenicity | Phase 3 | Completed | PT Bio Farma | 3071 | 2020-03-02 | 2022-01-04 |
| Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency Salmonella typhi polysaccharide vaccine - Immune Deficiency | Phase 1 | Completed | University of Virginia | 37 | 2019-07-01 | 2024-03-29 |
| Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali Pfs230D1M-EPA/AS01, HAVRIX, TYPHIM Vi (Salmonella typhi vaccine) - Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1301 | 2019-04-24 | 2024-10-22 |
| Inflammation and Threat Sensitivity in PTSD Typhoid Vi Polysaccharide Vaccine, Placebo - Posttraumatic Stress Disorder | Early Phase 1 | Completed | University of California, San Francisco | 30 | 2019-04-01 | 2021-05-13 |
| Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation Typhoid Vaccine, Ascorbic Acid - Aging, Inflammation | Phase 4 | Terminated | University of Illinois at Chicago | 35 | 2019-03-25 | 2021-11-12 |
| Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults EuTCV, Typbar-TCV™, Typhim Vi® - Typhoid Fever | Phase 1 | Completed | EuBiologics Co.,Ltd | 75 | 2019-03-16 | 2019-12-09 |
| Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants Vi-DT Vaccine, Vi Polysaccharide Vaccine, IPV Vaccine - Safety Issues, Immunogenicity | Phase 2 | Completed | PT Bio Farma | 600 | 2018-07-16 | 2020-02-20 |
| Cognitive, Emotional, and Neural Responses to Acute Inflammation Typhoid Vi Polysaccharide Vaccine, Placebo - Healthy | Early Phase 1 | Completed | University of California, San Francisco | 24 | 2018-01-01 | 2019-06-25 |
| Effects of Aging on Primary and Secondary Vaccine Responses Fluzone® quadrivalent, Fluzone High Dose, Fluad - Influenza, Hepatitis A | Phase 1 | Completed | Stanford University | 54 | 2017-09-19 | 2024-12-16 |
| Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I) Vi-DT (Bio Farma), Vi polysaccharide vaccine, Influenzae vaccine - Safety Issues | Phase 1 | Completed | PT Bio Farma | 100 | 2017-04-18 | 2018-03-06 |
| Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine Vi-DT, Typhim Vi®, VAXIGRIP® - Typhoid | Phase 1 | Completed | International Vaccine Institute | 144 | 2016-05-19 | 2020-04-28 |
| Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation Typhoid vaccine, Concentrate beetroot Juice, Concentrate beetroot Juice (Placebo) - Cardiovascular Diseases | Phase 1 | Completed | Queen Mary University of London | 78 | 2016-04-01 | 2022-07-20 |
| Polysaccharide Antibody Response Study Pneumovax 23 (Sanofi Pasteur MSD), Typhim Vi (Sanofi Pasteur MSD) - Specific Polysaccharide Antibody Deficiency | Phase 4 | Completed | Universitaire Ziekenhuizen KU Leuven | 200 | 2015-10-01 | 2024-07-15 |
| Vaccines Against Salmonella Typhi Vi-TCV, Vi-PS Vaccine, Control (Men ACWY) - Typhoid Fever, Enteric Fever | Phase 2 | Completed | University of Oxford | 112 | 2015-09-01 | 2022-07-05 |
Showing 20 of 33. Sign in to see all of them.
Typhoid Fever (12) · Paratyphoid Fever (5) · Inflammation (4) · Salmonella Infections (3) · Anemia, Iron-Deficiency (2) · Acute Coronary Syndrome (1) · Anemia (1) · Bacterial Infections (1) · Cardiovascular Diseases (1) · Dengue (1) · Depression (1) · Depressive Disorder, Major (1) · Diarrhea (1) · Dysentery, Bacillary (1) · Encephalitis, Japanese (1)
International Vaccine Institute (5) · GlaxoSmithKline (3) · PT Bio Farma (3) · Novartis (2) · Queen Mary University of London (2) · Sanofi Pasteur, a Sanofi Company (2) · University of California, San Francisco (2) · University of Oxford (2) · EuBiologics Co.,Ltd (1) · Janssen Pharmaceutica N.V., Belgium (1) · Karolinska Institutet (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nicole Stoffel (1) · Radboud University Medical Center (1) · Stanford University (1)
Belgium (6) · United States (6) · Indonesia (3) · Kenya (3) · United Kingdom (3) · Vietnam (2) · China (1) · Czechia (1) · Germany (1) · India (1) · Japan (1) · Malawi (1) · Mali (1) · Netherlands (1) · Pakistan (1)
Aoife S O'Donovan, PhD (2) · Bernie Endyarni, MD (2) · Amrita Ahluwalia, BSC PhD (1) · Amrita Ahluwalia, BSc PhD (1) · Andrew J Pollard, FRCPCH, PhD (1) · Ann L Sharpley, BSc, PhD (1) · Bernie E Medise, MD (1) · Canh G Do, MD (1) · Cornelia Dekker, MD (1) · Dong Baiqing, MD (1) · Elizabeth Schroeder, MS (1) · Isabelle Meyts, MD, PhD (1) · Larry Borish, MD (1)
PMID 19625715, PMID 21980445, PMID 24873986, PMID 25308927, PMID 27503474, PMID 27893465, PMID 28965718, PMID 29776750, PMID 30423462, PMID 31877141, PMID 32004693, PMID 32065303, PMID 33059607, PMID 33849723, PMID 36875126, PMID 37402153, PMID 38297337, PMID 38853614, PMID 39245584, PMID 39787798, PMID 40209616, PMID 40701160, PMID 41587557, PMID 42234814
2014 (2), K01MH109871 (2), R01AI130398 (1)